|
|
|
| Clinical effect of Liraglutide combined with Metformin in the treatment of type 2 diabetes mellitus |
| WANG Ming-wei |
| Department of Endocrinology, Changping District Hospital, Beijing 102200, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Liraglutide combined with Metformin in the treatment of type 2 diabetes mellitus. Methods A total of 80 patients with type 2 diabetes admitted to Beijing Changping District Hospital from January 2020 to January 2021 were selected as research objects, according to random number table method,they were divided into control group (40 cases) and study group (40 cases), the control group was treated with Metformin combined with Glimepiride, and the study group was treated with Metformin combined with Liraglutide. Therapeutic effect, blood glucose, islets β-cell function, blood lipid, body mass index (BMI), and adverse reactions were compared between the two groups. Results The efficacy of study group was higher than that of control group, and the difference was statistically significant (P<0.05). The levels of HbA1c, fasting blood glucose and 2 h postprandial blood glucose in the study group after treatment were lower than those in the control group, with statistical significance (P<0.05). After treatment, fasting insulin, β cell secretion index of the homeostasis model and islet resistance index of the homeostasis model in the study group were lower than those in the control group, and the differences were statistically significant (P<0.05). The indexes of total cholesterol, triglyceride and low density lipoprotein cholesterol in the study group after treatment were lower than those in the control group, and the differences were statistically significant (P<0.05). After treatment, the BMI of the study group was lower than that of the control group, and the difference was statistically significant (P<0.05). There was no statistical significance in the total incidence of adverse reactions between two groups (P>0.05). Conclusion The implementation of Liraglutide combined with Metformin therapy can significantly improve the treatment effect of type 2 diabetes mellitus, which is beneficial to effectively reduce blood glucose, BMI,improve lipid profile and pancreatic islet function in patients with high safety, without obvious side effects, and is worthy of promotion.
|
|
|
|
|
|
| [1] |
贾永军.二甲双胍联合艾塞那肽对超重2 型糖尿病患者糖脂代谢及体重指数的影响[J].内蒙古医学杂志，2020，52（12）：1437-1438.
|
| [2] |
刘艺丹.利拉鲁肽联合二甲双胍对2 型糖尿病的影响[J].山西卫生健康职业学院学报，2020，30（6）：26-28.
|
| [3] |
刘枘岢，陈毅光，李雯翀，等.二甲双胍联合利拉鲁肽治疗肥胖2 型糖尿病的临床疗效及安全性评价[J].当代临床医刊，2020，33（6）：557，575.
|
| [4] |
倪刚.二甲双胍治疗社区老年2 型糖尿病的效果与安全性[J].糖尿病新世界，2018，21（6）：189-190.
|
| [5] |
谭秋玲，罗小静，陈俏蓉.利拉鲁肽联合二甲双胍、格列齐特对2 型糖尿病血糖指标、 降糖成效、 不良反应的影响[J].中国医药科学，2020，10（22）：62-64，91.
|
| [7] |
丘红梅，姚纪瑜，朱荔，等.利拉鲁肽联合二甲双胍治疗初诊2 型糖尿病合并肥胖的临床疗效观察[J].实用糖尿病杂志，2020，16（4）：68.
|
| [8] |
邢英，闫军，郑嵘炅，等.利拉鲁肽与二甲双胍对超重2 型糖尿病患者肠道菌群的影响[J].中国医药，2020，15（11）：1732-1736.
|
| [9] |
岳扬，杨光，才蕊，等.利拉鲁肽及二甲双胍联合短期持续正压通气治疗2 型糖尿病伴阻塞性睡眠呼吸暂停综合征临床评价[J].中国药业，2020，29（20）：89-91.
|
| [6] |
Ticinovic Kurir T，Milicevic T，Novak A，et al.Adropin-Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide[J].Acta Clin Croat，2020，59（2）：344-350.
|
| [10] |
朱夏莺.二甲双胍联合利拉鲁肽注射液治疗2 型糖尿病患者的效果及对胰岛β 细胞功能、 胰岛素敏感性的影响[J].临床合理用药杂志，2020，13（29）：63-64.
|
| [11] |
雷翔森，盛新民，李春艳.利拉鲁肽联合二甲双胍治疗初诊肥胖2 型糖尿病患者的临床效果分析[J].实用糖尿病杂志，2020，16（5）：77-78.
|
| [12] |
陈兆君.利拉鲁肽联合二甲双胍治疗对2 型糖尿病合并冠状动脉粥样硬化性心脏病患者血脂水平、 心功能的影响[J].中国药物经济学，2020，15（10）：80-83.
|
| [13] |
王胜强.利拉鲁肽+二甲双胍治疗T2DM 的疗效及对内脂素水平的影响[J].微量元素与健康研究，2021，38（1）：14-15，20.
|
| [14] |
张启东，杨富平.利拉鲁肽与甘精胰岛素联合二甲双胍治疗2 型糖尿病的疗效对比[J].临床医学工程，2020，27（9）：1175-1176.
|
| [15] |
王婧.利拉鲁肽与二甲双胍联合治疗肥胖2 型糖尿病的效果及对胰岛β 细胞功能的影响[J].糖尿病新世界，2020，23（17）：69-71.
|
| [16] |
Simanenkova A，Minasian S，Karonova T，et al.Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance[J].Sci Rep，2021，11（1）：6700.
|
|
|
|
